Global /Netherlands /Healthcare /Drug Manufacturers - General /NAMS

NewAmsterdam Pharma Company N.V.

NAMS

• NASDAQ: NAMS • Delayed

28.41USD -1.1%

As of 12 June 2026, NewAmsterdam Pharma Company N.V. has a market cap of $3.27B USD, ranking #5123 globally and #43 in the Netherlands. It ranks #397 in the Healthcare sector, and #157 in the Drug Manufacturers - General industry.

Global Rank

5123

Country Rank

Sector Rank

397

Industry Rank

157

Key Stats

Market Cap

$3.27BUSD

Enterprise Value

$2.52BUSD

Revenue (TTM)

$22.5MUSD

EBITDA (TTM)

-$225.46MUSD

Net Income (TTM)

-$203.82MUSD

PS Ratio

144.3

PB Ratio

4.8

Company Profile

Country (HQ)

Netherlands

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Michael Davidson open_in_new

Employees

100

Founded

2019

Website

newamsterdampharma.com open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.1%	-13%	-6.1%	-12%	-22%	-20%	58%	98%	184%

News

NAMS Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	NAMS NewAmsterdam Pharma Co NV ISIN: NL00150012L7 Shares Out.: Shares Outstanding: 116.904M¹ Shares Float: 106.211M² TV: TradingView: NASDAQ: NAMS SA: Stock Analysis: NASDAQ: NAMS YF: Yahoo Finance: NAMS GF: Google Finance: NASDAQ: NAMS NQ: NASDAQ: NAMS BA: Barron's: NAMS MS: Morningstar: XNAS: NAMS	28.41 USD	TV: TradingView: NASDAQ: NAMS SA: Stock Analysis: NASDAQ: NAMS YF: Yahoo Finance: NAMS GF: Google Finance: NASDAQ: NAMS NQ: NASDAQ: NAMS BA: Barron's: NAMS MS: Morningstar: XNAS: NAMS

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Similar Companies

Industry: Drug Manufacturers - General (Netherlands)

Name	Market Cap (USD) diff.	PE	Country
Pharming Group N.V. AMS: PHARM	$1.16B 1.0B EUR -65%	412.1	Netherlands
ProQR Therapeutics N.V. NASDAQ: PRQR	$162.26M -95%	-	Netherlands

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 23K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 17K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 11K%	97.4	United States
Roche Holding AG SIX: RO	$320.56B 256.25B CHF 10K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.45B 215.59B GBP 9K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 8K%	15.1	United States

chevron_leftBack